Relevant bibliographies by topics / Lung cancer

Academic literature on the topic 'Lung cancer'

Author: Grafiati
Published: 4 June 2021
Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Lung cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Lung cancer"

1

Benkirane, Selma. "Skin metastases revealing lung cancer." Clinical Medical Reviews and Reports 2, no. 4 (August 10, 2020): 01–02. http://dx.doi.org/10.31579/2690-8794/024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pazos, Claribel. "Lung cancer: prevent or treat?" Biomedical Research and Clinical Reviews 4, no. 4 (August 30, 2021): 01–02. http://dx.doi.org/10.31579/2692-9406/073.

Full text
Abstract:
Cancer is currently one of the most serious health problems of humanity, it is among the first as a cause of death in developed and developing countries, with a tendency to continue to rise and occupy the absolute first place for the year 2025 also, because its diagnosis is made in advanced stages, it is estimated that its incidence will double by the year 2030 as a result of population growth and aging and that it may affect all ages, even those fetuses.
APA, Harvard, Vancouver, ISO, and other styles
3

Parida, Sheetal, Sumit Siddharth, and Dipali Sharma. "Role of Omentin in Obesity Paradox in Lung Cancer." Cancers 13, no. 2 (January 13, 2021): 275. http://dx.doi.org/10.3390/cancers13020275.

Full text
Abstract:
Lung cancer remains the second-most-common cancer worldwide and is associated with the highest number of cancer-related mortality. While tobacco smoking is the most important risk factor for lung cancer, many other lifestyles and occupational factors significantly contribute. Obesity is a growing global health concern and contributes to ~30% cancer-related mortality, but unlike other lifestyle diseases, lung cancer is negatively associated with obesity. We meta-analyzed multiple case-control studies confirming increased survival and better outcomes in overweight and obese lung cancer patients. Tumor heterogeneity analysis showed significant enrichment of adipocytes and preadipocytes in normal lungs compared to lung cancers. Interestingly, one of the understudied adipokine, omentin, was significantly and consistently lower in lung neoplasms compared to normal lungs. Omentin has been examined in relation to osteoarthritis, inflammatory bowel disease, cardiovascular diseases, diabetes, chronic liver disease, psoriasis and some other cancers. Aberrant expression of omentin has been reported in solid tumors; however, little is known about its role in lung cancer. We found omentin to be consistently downregulated in lung cancers, and it exhibited a negative correlation with important transcription factors FOXA1, EN1, FOXC1 and ELK4. We, therefore, suggest that omentin may serve as a prognostic factor in lung cancer and explain the “obesity paradox” in lung cancer.
APA, Harvard, Vancouver, ISO, and other styles
4

Garrepalli, Saritha. "Global Patterns of Lung Cancer Incidence." Cancer Research and Cellular Therapeutics 2, no. 2 (August 1, 2018): 01–03. http://dx.doi.org/10.31579/2640-1053/027.

Full text
Abstract:
Introduction It is well known that smoking is injurious to health which causes lung cancer. Although not all smokers develop lung cancer, fraction of lifelong non-smokers will die from lung cancer. Lung cancer is a major cause of cancer related death in developed countries with extremely poor overall survival rate. In present study we set out epidemiological pattern with clinical profile of lung cancer patients in northern india population. Aim:We evaluate the effect of smoking with age distribution on histopathology in lung cancer patients. Material & Methods: We enrolled 218 patients after confirmation of histopathology and also collected demographic data. Results: Out of 218 patients of lung cancer, having median age of 56 years, we found 149 (68.3%) were smokers and 69 (31.6%) were nonsmokers. In histopathology 54.1% patients had squamous cell carcinoma, 29.2% adenocarcinoma, 12.4% Mixed cell, 3.7% Small cell. We also found 63.1% smoker to have squamous cell carcinoma and 50.7% non-smoker have adenocarcinoma.In our study middle age group patients were more frequent in smoking group. While higher age group patients has squamous cell and middle group have adenocarcinoma. Therefore patients group with high smoking are found to develop have more risk to develop small cell carcinoma rather than in case of non-smoker higher age groups have sqamous cell carcinoma type. Conclusion: In this study we found middle age group subjects of smoker having more squamous cell and nonsmoker having adenocarcinoma.
APA, Harvard, Vancouver, ISO, and other styles
5

Srivastava, A. N., Neema Tiwari, Shailendra Yadav, and Suryakant . "LUNG CANCER STEM CELLS-AN UPDATE." Era's journal of medical research 4, no. 1 (June 1, 2017): 22–31. http://dx.doi.org/10.24041/ejmr2017.4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Taylor, Jacob, Adam B. Weiner, Binhuan Wang, Arjun V. Balar, Gary D. Steinberg, and Richard S. Matulewicz. "Lung Metastases Versus Second Primary Lung Cancers in Patients with Primary Urothelial Carcinoma of the Bladder: A National Population-Based Assessment." Bladder Cancer 7, no. 3 (August 31, 2021): 347–54. http://dx.doi.org/10.3233/blc-210008.

Full text
Abstract:
BACKGROUND: The work-up and diagnosis of indeterminate lung nodules at time of bladder cancer diagnosis may delay or change treatment. OBJECTIVE: To quantify the incidence of synchronous and metachronous lung cancers in adults with bladder cancer and compare these rates to the incidence of bladder cancer metastases in the lung. METHODS: We retrospectively analyzed all adults diagnosed with bladder cancer in the Surveillance, Epidemiology and End Results (SEER) registry (2010– 2015) and identified second primary lung cancers defined as being either synchronous (diagnosed within 6 months of bladder cancer diagnosis) or metachronous (more than 6 months following index bladder cancer diagnosis). The risk of second primary lung cancers were reported as a standardized incidence ratio (SIR) reflecting observed and expected case ratios. RESULTS: A total of 88,335 patients diagnosed with bladder cancer were included. Among adults with NMIBC (n = 66,071) and MIBC (n = 18,879), 0.3% and 3.9% had bladder cancer metastatic to the lungs at diagnosis. Synchronous second primary lung cancers were diagnosed in 0.4% and 0.7% of patients with NMIBC and MIBC, respectively. Compared to the general population, the SIR for synchronous lung cancers among adults with NMIBC was 2.5 (95% CI 2.3– 2.9) and was 4.7 (95% CI 4.0– 5.6) for adults with MIBC. CONCLUSIONS: Bladder cancer metastatic to the lung is more common in adults with MIBC compared to NMIBC. There are similar frequencies of synchronous second primary lung cancers regardless of initial bladder cancer stage.
APA, Harvard, Vancouver, ISO, and other styles
7

Sankar, V., R. Kothai, and N. Vanisr. "Lung Cancer - A Review." International Journal of Health Sciences and Research 13, no. 10 (October 26, 2023): 307–15. http://dx.doi.org/10.52403/ijhsr.20231042.

Full text
Abstract:
Lung cancer is the prime cause of cancer death among both men and women according to WHO report 2.09 million cases globally. It is also the chief cause of cancer death among men and the second leading cause of cancer death among women worldwide. The lung cancer classified into two different types are small-cell lung cancers (SCLC) and non-small-cell lung cancers (NSCLC). Non-small cell lung cancer is more common than small cell lung cancer. Treatment of lung cancer may involve a combination of surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy. Therapeutic recommendations depend on several factors, including stage and type of cancer. Low- and middle-income countries now account for more than 50 % of lung cancer deaths each year the responses to current standard therapies are poor except for the most localized cancers. The purpose of this review is to sum up the types, epidemiology, detection, metastasis and the treatment of lung cancer. Key words: WHO, SCLC, NSCLC, Epidemiology, Metastasis
APA, Harvard, Vancouver, ISO, and other styles
8

Zheng, Xiaohu, Weihua Xiao, and Zhigang Tian. "869 Anti-LunX targeting therapy for lung cancer." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (November 2020): A921. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0869.

Full text
Abstract:
BackgroundThe identification of novel therapeutic targets in lung cancer for the generation of targeted drugs is an urgent challenge. Lung-specific X (LunX) is a member of the palate, lung, and nasal epithelium clone (PLUNC) protein family. Some reports have suggested that the human PLUNC gene (also named LUNX) might be a potential marker for NSCLC, and PLUNC mRNA has been identified in peripheral blood and mediastinal lymph nodes from NSCLC patients.It is unclear whether LunX expression is associated with the pathological type and pathological severity in lung cancer patients. The utility of LunX as a potential therapeutic target in NSCLC is uncertain.MethodsClinically, 80% of lung cancers are non-small-cell lung cancers (NSCLCs). Here, we analyzed 158 NSCLC samples and detected LunX expression.ResultsIt showed that the expression of LunX were elevated in 90% (108/150) lung cancers by IHC staining, which accompanied with significantly lower rate of postsurgery survival. Further evaluation of LunX expression in invasive tumor cells in subclavicular lymph nodes, draining lymph nodes, hydrothorax of lung cancer patients, turned out that LunX is highly expressed in invasive lung cancer cells. These data indicated that LunX overexpresses in lung cancer and associates with tumorigenesis and tumor progression.Mechanistically, we discovered that LunX bound to 14-3-3 protein and facilitated their activation by maintaining these proteins in a dephosphorylated state, thereby contributing to the activation of pathways downstream of 14-3-3 protein, such as the Erk1/2 and JNK pathways. Thus, LunX promoted tumor growth and metastasis.Furthermore, we generated a therapeutic antibody specific for lung cancer, which not only inhibited lung cancer growth and reduced Ki67 staining and angiogenesis in xenograft model of subcutaneously transplanted tumor, but also blocked tumor metastasis and invasion, improved the survival of these mice. We also detected that antibody treatment induces LunX antigen-antibody complex endocytosis and the degradation of LunX protein.ConclusionsOur study suggests that LunX is a novel therapeutic target in lung cancer and that the LunX-targeted therapeutic antibody may have considerable clinical benefit.
APA, Harvard, Vancouver, ISO, and other styles
9

Greschuchna, D. "Surgical Treatment of Small Cell Lung Cancer." Journal of the Japanese Association for Chest Surgery 3, no. 2 (1989): 169. http://dx.doi.org/10.2995/jacsurg1987.3.2_169.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dartevelle, Philippe. "Results of Carinal Resection for Lung Cancer." Journal of the Japanese Association for Chest Surgery 11, no. 3 (1997): 291. http://dx.doi.org/10.2995/jacsurg.11.291.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Lung cancer"

1

Gaskin, Janet. "Radon and Lung Cancer." Thesis, Université d'Ottawa / University of Ottawa, 2019. http://hdl.handle.net/10393/39003.

Full text
Abstract:
Background: Lung cancer was the fifth leading cause of mortality globally in 2010, and the leading cause of cancer mortality in Canada, representing 26% of all cancer deaths for both men and women in 2017. Radon is a very modifiable environmental exposure that is the second most important cause of lung cancer. Objectives: The objectives of this thesis are to quantify the lung cancer burden associated with residential radon and to identify the most cost effective mitigation options to reduce residential radon in Canada. Methods: The global burden of lung cancer mortality attributable to radon in 2012 was estimated from the 66 countries for which a representative national radon survey was available, using several different models for excess relative risk (ERR) of lung cancer from radon studies. Cost-utility analyses are conducted for 20 practical radon interventions scenarios to reduce residential radon exposures in new and existing housing in Canada, each province/territory and 17 census metropolitan areas. A societal perspective and a lifetime horizon are adopted. A Markov cohort model and a discrete event simulation are used to model residents by household, based on a period-life table analysis, at a discount rate of 1.5%. Results: The estimates of the global median PAR were consistent, ranging from 16.5% to 13.6% for the three ERR models based on miners, and the mean estimates of PAR for Canada ranged from 16.3% to 14.6%. It is very cost effective to install radon preventive measures in new construction compared to no radon control in all regions across Canada. At a radon mitigation threshold of 100 Bq/m3, the sequential analysis recommends the combination of the activation of preventive measures in new housing with the mitigation of existing housing at current testing and mitigation rates for cost effectiveness thresholds between 51,889 and 92,072 $/QALY for Canada, between 27,558 and 85,965 $/QALY for Manitoba, and between 15,801 and 36,547 $/QALY for the Yukon. The discounted ICER for screening and mitigation of existing housing at current rates relative to no radon control measures is 62,451 (66,421) $/QALY using a Markov cohort model (discrete event simulation model) for mitigation of housing above a threshold of 200 Bq/m3, and is 58,866 (59,556) $/QALY using a Markov cohort model (discrete event simulation model) for mitigation of housing above a threshold of 100 Bq/m3. Conclusions: Cost effective residential radon interventions should be implemented across Canada to reduce exposures to this very modifiable cause of lung cancer and to help reduce the increasing lung cancer burden in an ageing Canadian population.
APA, Harvard, Vancouver, ISO, and other styles
2

Thomas, Akesh, zainab Fatima, and Girendra resident Hoskere. "Lung Cancer in Tennessee." Digital Commons @ East Tennessee State University, 2021. https://dc.etsu.edu/asrf/2021/presentations/69.

Full text
Abstract:
Introduction Lung cancer is the most common cause of cancer-related death in the United States (US). Tobacco smoking is a well-recognized cause of lung cancer. About 2% of the United States (US) population lives in Tennessee (TN). Nearly 21 % of TN adults are current smokers as per 2019 data, compared to 14% across the US. The percentage of smokers has historically been high in TN and its surroundings. This can be attributed to the area's socio-economic and cultural characteristics, along with large areas of tobacco farming in the region. This increases the risk of lung cancer in the TN population. Surveillance Epidemiology and End Results Program (SEER) is a collection of cancer registries across the US, covering about 35% of the US population (TN cancer registry is not a part of SEER). Our study compares lung cancer incidence and characteristics in the TN cancer registry with the SEER 18 registry. Materials and Methods Data were collected from the TN cancer registry and SEER separately for lung and bronchial cancer. Data was analyzed for different histological subtypes, age groups, gender, stage at diagnosis, and rural/urban residence. Stata and Microsoft Excel were used in data analysis. A Chi-square test was used to calculate the statistical significance. Results From 2008 to 2017, 58644 cases of lung cancer were reported in the Tennessee cancer registry. During the same period, 519112 cases were reported in the SEER registry. The most frequent histological subtype of lung cancer in TN and SEER was adenocarcinoma (frequency of 17,503 Vs. 182346), followed by squamous cell carcinoma and small cell carcinoma. Most cancers in TN and SEER were diagnosed at stage of distant metastasis (46% vs. 52% ), followed by regional metastasis, localized, and in situ (Image1). The frequency of lung cancer diagnosis was high among those older than 65 in TN and SEER (64% vs. 69%). Males had a higher incidence of lung cancer in both registries. Most lung cancers were reported in the urban area in both registries. Chronic obstructive pulmonary disease was the most commonly reported secondary diagnosis (3,099), followed by pleural effusion in the TN database; the comparable data were not available in SEER. Relative survival at 12 months and five years for lung cancer in TN were 46.6 % and 19.5 % (Vs. 46.4% and 19.9% in SEER) Discussion and Conclusion If both registries were perfect, then lung and bronchial cancer incidence will be 9241 and 6048 per million in ten years in TN and SEER, respectively. But after careful analysis, we conclude that such analysis will be erroneous. The proportion of different histological types, stage at diagnosis, age groups, and gender were in the same order in both groups. Although chi-square test values are significant for all the variables, we infer no conclusion considering the data's inherent bias. Further in-depth analysis of the data is required.
APA, Harvard, Vancouver, ISO, and other styles
3

Ruiz, Rossana, Marco Galvez-Nino, Ebert Poquioma, Abel Limache-García, Edgar Amorin, Mivael Olivera, Natalia Valdiviezo, et al. "Lung Cancer in Peru." Elsevier Inc, 2020. http://hdl.handle.net/10757/652438.

Full text
Abstract:
Peru is a South American nation with a growing and aging population of 31 million people with a life expectancy at birth of 76.7 years. The country is divided into 25 regions, 79% of the population is urban, and Lima, the capital, concentrates more than a third of the population.1 Although Peru is an upper-middle-income country, health expenditure represents only 5.1% of the gross domestic product, which is lower than the average of Latin America and the Caribbean (LATAM) (8.56%).2 Out-of-pocket health expenditure is 30.9%.3 Peru has a comprehensive National Cancer Plan and two population-based cancer registries in Lima and Arequipa.
Revisión por pares
APA, Harvard, Vancouver, ISO, and other styles
4

Salvati, Valentina. "Development of effective lung cancer therapies based on lung cancer stem cella targeting." Doctoral thesis, Università di Catania, 2015. http://hdl.handle.net/10761/4035.

Full text
Abstract:
Il carcinoma polmonare non a piccole cellule (NSCLC) rappresenta circa l 80% di tutti i tumori al polmone ed è il cancro più comune e più mortale al mondo. Il trattamento convenzionale per il NSCLC in stadio avanzato è stato basato per molto tempo sull uso della chemioterapia, ma con basso impatto sulla sopravvivenza . Una migliore comprensione dei meccanismi molecolari coinvolti nel processo di tumorigenesi e una maggiore capacità nell identificazione di specifiche alterazioni genetiche come bersagli terapeutici, hanno portato ad un significativo avanzamento verso lo sviluppo di terapie più efficaci. Il recettore del fattore di crescita dell epidermide (EGFR) è spesso over-espresso nel NSCLC ed è considerato un promettente bersaglio terapeutico per il trattamento di questo tumore. La presenza di mutazioni nel gene EGFR sono un importante predittore di risposta agli inibitori dell EGFR. Sebbene gli inibitori dell EGFR di prima generazione hanno mostrato incoraggianti risposte cliniche nei tumori al polmone, quasi tutti i pazienti sviluppano resistenza al trattamento nel corso del tempo. La resistenza ai trattamenti potrebbe dipendere anche dalla presenza delle cellule staminali tumorali (CSCs), una sottopopolazione di cellule intrinsecamente resistenti. Così, lo studio delle cellule staminali tumorali del polmone, potrebbe essere uno strumento efficace per l identificazione e validazione di bersagli terapeutici innovativi contribuendo all'introduzione di importanti miglioramenti nell ambito dell oncologia clinica. Pertanto, la terapia mirata verso l EGFR continua ad evolvere in seguito alla scoperta della sensibilità agli inibitori tirosin-chinasici da parte di pazienti caratterizzati da mutazioni attivanti del gene EGFR. Tuttavia, circa il 10-20% dei pazienti privi della mutazione dell EGFR, beneficiano anch essi del trattamento con gli inibitori TKIs, suggerendo che potrebbero esistere altri determinanti di risposta al trattamento, indipendenti dalla mutazione del recettore. Questo progetto, quindi, è stato focalizzato sull analisi della via di segnale dell EGFR e sullo studio della sensibilità delle cellule staminali tumorali di polmone e di modelli murini da esse derivati, agli inibitori dell EGFR, al fine di identificare possibili biomarcatori predittivi di risposta agli TKIs, in cellule prive della mutazione dell EGFR. Questo studio ha portato all identificazione della fosforilazione dell EGFR al residuo tirosina 1068, ma non 1173, come potenziale marcatore di risposta all Erlotinib nelle cellule staminali tumorali di polmone e negli xenografts da esse derivati. Inoltre, anche linee cellulari commerciali di polmone sensibili all Erlotinib, esprimevano pEGFR-tyr-1068 indipendentemente dalla mutazione dell EGFR, così, l espressione di pEGFR-tyr1068 nelle cellule staminali tumorali di polmone è risultata essere associata ad una risposta positiva al trattamento con l Erlotinib. La valutazione, mediante immunoistochimica, dello stato di fosforilazione dell EGFR in pazienti con mutazione e senza mutazione del recettore, ha portato a correlare solo pEGFR-tyr1068 e non pEGFR-tyr1173, con la mutazione dell EGFR. In base a questi dati, quindi, è possibile ipotizzare che l identificazione del livello di fosforilazione dell EGFR al residuo tirosina 1068 nei tumori dei pazienti, permetterebbe di individuare tumori con e senza mutazione dell EGFR ma caratterizzati da attivazione del recettore, in grado probabilmente di rispondere in modo positivo al trattamento con l Erlotinib. Questi studi potrebbero avere importanti implicazioni terapeutiche per il trattamento dei tumori al polmone e potrebbero permettere ai pazienti con NSCLC di essere selezionati per terapie più efficaci e meno tossiche.
APA, Harvard, Vancouver, ISO, and other styles
5

Şeşen, Mustafa Berkan. "Lung cancer assistant : a hybrid clinical decision support application in lung cancer treatment selection." Thesis, University of Oxford, 2013. https://ora.ox.ac.uk/objects/uuid:e0dd01e4-3f18-49ed-89af-5e81894d4967.

Full text
Abstract:
We describe an online clinical decision support (CDS) system, Lung Cancer Assistant (LCA), which we have developed to aid the clinicians in arriving at informed treatment decisions for lung cancer patients at multidisciplinary team (MDT) meetings. LCA integrates rule-based and probabilistic decision support within a single platform. To our knowledge, this is the first time this has been achieved in the context of CDS in cancer care. Rule-based decision support is achieved by an original ontological guideline rule inference framework that operates on a domain-specific module of Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT), containing clinical concepts and guideline rule knowledge elicited from the major national and international guideline publishers. It adopts a conventional argumentation-based decision model, whereby the decision options are listed along with arguments derived by matching the patient records to the guideline rule base. As an additional feature of this framework, when a new patient is entered, LCA displays the most similar patients to the one being viewed. Probabilistic inference is provided by a Bayesian Network (BN) whose structure and parameters have been learned based on the English Lung Cancer Database (LUCADA). This allows LCA to predict the probability of patient survival and lay out how the selection of different treatment plans would affect it. Based on a retrospective patient subset from LUCADA, we present empirical results on the treatment recommendations provided by both functionalities of LCA and discuss their strengths and weaknesses. Finally, we present preliminary work, which may allow utilising the BN to calculate survival odd ratios that could be translated into quantitative degrees of support for the guideline rule-based arguments. An online version of LCA is accessible on http://lca.eng.ox.ac.uk.
APA, Harvard, Vancouver, ISO, and other styles
6

Turner, Nicola Jane. "Cancer in older people : studies in lung cancer." Thesis, University of Leeds, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.399662.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

OLSSON, MILLA, and CAROLINE ROSELL. "Telemedicine for Lung Cancer Patients." Thesis, KTH, Skolan för datavetenskap och kommunikation (CSC), 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-136951.

Full text
Abstract:
Den svenska sjukvården står idag för ett antal utmaningar om den skall fortsatt kunna erbjuda god service som vårdgivare och vara attraktiv som arbetsgivare. Bland annat diskuteras frågor som förvärrad platsbrist, läkarbrist samt avstånd till specialistsjukvård. På Karolinska Universitetssjukhuset i Solna ligger Radiumhemmet och där behandlas bland annat lungcancerpatienter. Där diskuteras huruvida telemedicin kan vara en möjlig väg för att lösa ovanstående problem. Denna uppsats utreder på vilket sätt telemedicin kan användas på Radiumhemmet för lungcancerpatienter. För att kunna utreda en telemedicinsk lösnings möjligheter på Radiumhemmet genomfördes intervjuer och fokusgrupper med personalen. Externa experter från sjukvården och industri intervjuades och ett besök gjordes på barnsjukhuset Childrens Healthcare of Atlanta, USA, där man har kommit långt i användningen av telemedicin. Det finns delar av verksamheten på Radiumhemmet där telemedicin skulle kunna bidra till att skapa möjligheter till en tätare kontakt mellan patient och vårdpersonal. Detta i syfte att lugna oroliga patienter och hjälpa till med lättare symptombedömningar och på så sätt minska väntetiderna. Genom de undersökningar som utfördes upptäcktes dock även svagheter i en telemedicinsk lösning avsedd för lungcancerpatienter. Patientgruppen ofta är äldre med liten erfarenhet av datorer och sjukdomen är allvarlig. Det krävs personlig kontakt och fysiska undersökningar, men i vilken utsträckning är individuellt. Telemedicin kanske inte kan ses som en absolut lösning för de problem som råder i sjukvården idag när det kommer till lungcancerpatienter, men väl som ett komplement. Om lungcancerpatienter är den optimala målgruppen är ifrågasättbart men att telemedicin kan underlätta i den svenska sjukvården står klart.
Nowadays the health care system in Sweden is faced with several challenges like shortage of space, physicians and long distances to specialized health care. A possible solution for this being discussed at the lung cancer department of Karolinska University 2 Hospital is the use of telemedicine. If implemented it would be part of the followup treatment. The objective of our research is to find out if this technology can help improve the health care. In order to investigate the opportunity for a telemedicine solution, we collected qualitative data from multiple different sources. This included two doctors specialized in lung cancer, and a focus group with nurses from Radiumhemmet. We also conducted interviews with relevant individuals outside the hospital including Nirav Desai who is the Founder and CEO of Hands On Telehealth; furthermore, we visited the Children’s Healthcare of Atlanta based in Atlanta, Georgia where telemedicine is used on a daily basis. Thanks to the carried out research, we have discovered that telemedicine could be used in certain scenarios and contribute towards a more frequent contact between the patient and the medical professionals. Thus, this new technique could help nurses execute lighter symptoms assessment remotely and reduce waiting times. We also discovered some inconveniences in a telemedicine solution designed for lung cancer patients. We personally do not think they are the best target group for such a solution since the patients are mostly the elderly with little computer experience. Also the disease is severe and requires physical examinations where the telemedicine existing today would not improve the care giving. To all intents and purposes, telemedicine might not be the only and ultimate solution for the problems identified within healthcare for lung cancer patients at Radiumhemmet, but it can work well as a supplement. 3
APA, Harvard, Vancouver, ISO, and other styles
8

Basran, Parminder S. "Optimisation of lung cancer treatment." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/mq22568.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tinnemans, Monique Maria Franciska Johanna. "Cytokinetic analysis of lung cancer." Maastricht : Maastricht : Universitaire Pers Maastricht ; University Library, Maastricht University [Host], 1996. http://arno.unimaas.nl/show.cgi?fid=7289.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Richards, Elizabeth. "Molecular profiling of lung cancer." Thesis, Imperial College London, 2013. http://hdl.handle.net/10044/1/24546.

Full text
Abstract:
Cisplatin is a first line chemotherapeutic agent for lung cancer however, although patients may respond to therapy, resistance often develops with tumour recurrence and disease progression. Somatic alterations in the tumour may alter therapeutic responses. Consequently a model of cisplatin resistance in lung cancer derived A549 cells has been created to examine the genomic changes that occur as chemo-resistance develops. Drug resistance was induced in A549 cells through multiple rounds of cisplatin dosage and recovery over two different time courses. The concentration of cisplatin required to inhibit growth (inhibitory concentration [IC] value) was calculated at each round and cycles were continued until the IC value increased at least four-fold. Cells were harvested and total RNA extracted for whole transcriptome microarray analysis. Data was analysed using R statistics and associated packages, Affy, Limma, Mfuzz and WGCNA. A five-fold increase in IC value was generated over successive doses in both regimes, accompanied by highly significant changes in gene expression. To explore these changes, temporal expression clustering and extensive network analyses were performed across the rounds of cisplatin dosing, as well as an untreated cell culture time course that acted as a comparison to the two treated regimes. The results gathered from this robust model suggest that differences in dose and frequency of chemotherapy may affect genomic changes at specific loci that confer cisplatin resistance. Interesting and relevant pathways and genes have been discovered. In combination with analyses on a small patient cohort, these results have provided insights into the mechanism of cisplatin resistance and have highlighted new clinical biomarkers of potential use in prognosis of patients undergoing cancer treatment.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Lung cancer"

1

Joseph, Aisner, ed. Lung cancer. New York: Churchill Livingstone, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

A, Roth Jack, Cox James D. 1938-, and Hong Waun Ki, eds. Lung cancer. Boston: Blackwell Scientific Publications, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hirsch, Fred R. Lung cancer. London: Remedica, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ginsberg, Robert J. Lung cancer. Hamilton, Ont: BC Decker, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Driscoll, Barbara. Lung Cancer. New Jersey: Humana Press, 2002. http://dx.doi.org/10.1385/1592593232.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Driscoll, Barbara. Lung Cancer. New Jersey: Humana Press, 2002. http://dx.doi.org/10.1385/1592593240.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Falk, Stephen A. Lung cancer. New York: Oxford University Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Santiago-Cardona, Pedro G., ed. Lung Cancer. New York, NY: Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1278-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chiang, Anne C., and Roy S. Herbst, eds. Lung Cancer. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-74028-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Leary, Alison, ed. Lung Cancer. West Sussex, UK: John Wiley & Sons, Ltd., 2012. http://dx.doi.org/10.1002/9781118702857.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Lung cancer"

1

Bhatia, Sujata K. "Lung Cancer Chapter 9 Lung cancer." In Biomaterials for Clinical Applications, 183–211. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-6920-0_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Worden, Francis P., and Gregory P. Kalemkerian. "Lung Cancer." In Cancer Treatment and Research, 183–219. Boston, MA: Springer US, 2001. http://dx.doi.org/10.1007/978-1-4615-1657-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yamamoto, Naoyoshi, and Mio Nakajima. "Lung Cancer." In Carbon-Ion Radiotherapy, 177–89. Tokyo: Springer Japan, 2013. http://dx.doi.org/10.1007/978-4-431-54457-9_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Shah, Alap, and Daniel Hunter-Smith. "Lung Cancer." In Family Medicine, 1103–10. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-04414-9_92.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wedding, Ulrich. "Lung Cancer." In Cancer and Aging Handbook, 283–314. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2013. http://dx.doi.org/10.1002/9781118312513.ch20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dobra, Katalin, and Anders Hjerpe. "Lung Cancer." In Serous Effusions, 171–89. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-76478-8_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dobra, Katalin, and Anders Hjerpe. "Lung Cancer." In Serous Effusions, 151–65. London: Springer London, 2011. http://dx.doi.org/10.1007/978-0-85729-697-9_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zimmermann, Stefan, Alessandra Curioni Fontecedro, Rolf A. Stahel, and Solange Peters. "Lung Cancer." In Side Effects of Medical Cancer Therapy, 119–38. London: Springer London, 2012. http://dx.doi.org/10.1007/978-0-85729-787-7_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Beyzadeoglu, Murat, Gokhan Ozyigit, Ugur Selek, and Ugur Selek. "Lung Cancer." In Radiation Oncology, 251–67. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-27988-1_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nestle, Ursula, Sonja Adebahr, and Tanja Schimek-Jasch. "Lung Cancer." In Target Volume Definition in Radiation Oncology, 91–113. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-662-45934-8_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Lung cancer"

1

Patel, Sagar S., Ramesh Natarajan, and Rebecca L. Heise. "Mechanotransduction of Primary Cilia in Lung Adenocarcinoma." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80435.

Full text
Abstract:
Lung cancer causes more than 1 million deaths worldwide annually [1]. In a recent study by the American Cancer Society in 2011, more than 221,000 new cases of lung cancers were reported [2]. Out of these, the mortality rate was found in roughly 70% of the cases [2]. Lung cancer is divided into two major categories: small cell and non-small cell. In the United States, non-small cell lung cancer accounts for 85% of all lung cancers and is considered the most common type of lung cancer [2]. It is usually resistant to chemotherapy, therefore making it extremely difficult to treat [3]. Furthermore adenocarcinomas, a type of non-small cell lung cancer, occur towards the periphery of the lungs and are the most common type accounting for 40–45% of all lung cancer cases [3]. Epithelial cells in the healthy lungs undergo stresses during inhalation and expiration of normal breathing. In addition to the forces of normal breathing, lung cancer cells may also experience abnormal mechanical forces due to pre-existing lung diseases such as asthma, bronchitis and chronic obstructive pulmonary disease or other tumor associated structural changes. These conditions can significantly alter the structure of the lungs and cell phenotype [4]. The change in the structure of the lungs affects the mechanical environment of the cells. Changes in extracellular (ECM) stiffness, cell stretch, and shear stress influence tumorigenesis and metastasis [5]. One mechanism through which the cells sense and respond to the cellular mechanical environment is through the primary cilia [6–7]. Primary cilia are non-motile, solitary structures formed from the cellular microtubules and protrude out of each cell. They have also been shown to play an important role in facilitating common cancer signaling pathways such as Sonic Hedgehog and Wnt/β-catenin signaling [8–9]. The objective of this study was to test the hypothesis that lung cancer cells respond to mechanical stimuli with the formation of primary cilia that are necessary for 3 hallmarks of tumor progression: proliferation, epithelial mesenchymal-transition, and migration.
APA, Harvard, Vancouver, ISO, and other styles
2

Hider, Nabilah Hanani, Anis Salwa Binti Mohd Khairuddin, and Effariza Binti Hanafi. "VGG Classification Model for Lung Cancer Diagnosis." In International Technical Postgraduate Conference 2022. AIJR Publisher, 2022. http://dx.doi.org/10.21467/proceedings.141.9.

Full text
Abstract:
Lung cancer is one of the most common cancers worldwide that leads to small survival rate. It is important to detect the presence of these harmful cells in human body at early stages to prevent it from worsening. The primary goal of this study is to propose an efficient lung cancer image classification model using deep learning method. The cancer image classification framework is proposed by using transfer learning with Convolutional Neural Network (CNN) to classify three categories of 5,100 cancer images namely lung adenocarcinoma, lung squamous cell carcinoma and benign lung tissues obtained from the dataset. Several experiments have been performed to improve the VGG19 model performance by varying the optimizers including RMSprop, Adam and SGD. The performance of all experiments conducted were analyzed based on the training and validation curves, classification reports and the confusion metrics.
APA, Harvard, Vancouver, ISO, and other styles
3

Olsson, A., and H. Kromhout. "OCCUPATIONAL CANCER BURDEN: THE CONTRIBUTION OF EXPOSURE TO PROCESS-GENERATED SUBSTANCES AT THE WORKPLACE." In The 16th «OCCUPATION and HEALTH» Russian National Congress with International Participation (OHRNC-2021). FSBSI “IRIOH”, 2021. http://dx.doi.org/10.31089/978-5-6042929-2-1-2021-1-617-620.

Full text
Abstract:
Abstract. Occupational exposure to respirable crystalline silica, diesel engine exhaust emissions and welding fumes are widespread risk factors for lung cancer, and account for approximately half of the occupational lung cancer burden. If employers succeed in controlling workplace exposures to these process-generated substances, the fraction of lung cancers attributable to occupational exposures could be reduced dramatically.
APA, Harvard, Vancouver, ISO, and other styles
4

Ludeke, D. Taylor, and Maj Dedin Mirmirani. "The Pulling Device for a Flexible Bronchoscope." In ASME 2006 Frontiers in Biomedical Devices Conference. ASMEDC, 2006. http://dx.doi.org/10.1115/nanobio2006-18045.

Full text
Abstract:
The flexible bronchoscope, used both to directly visualize and biopsy lesions, is an important tool for diagnosing lung cancer [1]. Presented here is a conceptual design for a device that increases the depth to which the scope can be fed into the lungs. This allows doctors to find and accurately diagnose more cases of lung cancer first occurring deeper in the lungs.
APA, Harvard, Vancouver, ISO, and other styles
5

"Lung Cancer Prediction Using Machine Learning: A Systematic Review." In International Conference on Women Researchers in Electronics and Computing. AIJR Publisher, 2021. http://dx.doi.org/10.21467/proceedings.114.3.

Full text
Abstract:
One of the large spread diseases in a human being is Lung Cancer. It remains a threat to society and is the cause of thousands of deaths worldwide. Early detection cause of lung cancer is an understandable perspective to maximize the opportunity of the existence of the patients. This paper is about the observation of lung cancer. Here, Computed Tomography (CT) is used for the observation of lung cancer. Various Algorithms are used to search out lung cancer prediction correctly like K Nearest Neighbor, SVM, Decision Tree, and many more. An Aim of the introduced analysis to design a model that can reduce the likelihood of lung cancer in a patient with maximum accuracy. We began by surveying various machine learning techniques, explaining a concise definition of the most normally used classification techniques for identifying lung cancer. Then, we analyze survey representable research works utilizing learning machine classification methods in this field. Moreover, an elaborated comparison table of surveyed paper is introduced.
APA, Harvard, Vancouver, ISO, and other styles
6

Saghir, Zaigham, and Constance de Koning. "Lung cancer screening in Denmark." In Nordic Lung Congress 2022, edited by Zaigham Saghir and Vibeke Backer. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/6c4e8d8d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Garg, Priya, and Deepti Aggarwal. "Application of Swarm-Based Feature Selection and Extreme Learning Machines in Lung Cancer Risk Prediction." In Intelligent Computing and Technologies Conference. AIJR Publisher, 2021. http://dx.doi.org/10.21467/proceedings.115.1.

Full text
Abstract:
Lung cancer risk prediction models help in identifying high-risk individuals for early CT screening tests. These predictive models can play a pivotal role in healthcare by decreasing lung cancer's mortality rate and saving many lives. Although many predictive models have been developed that use various features, no specific guidelines have been provided regarding the crucial features in lung cancer risk prediction. This study proposes novel risk prediction models using bio-inspired swarm-based techniques for feature selection and extreme learning machines for classification. The proposed models are applied on a public dataset consisting of 1000 patient records and 23 variables, including sociodemographic factors, smoking status, and lung cancer clinical symptoms. The models, validated using 10-fold cross-validation, achieve an AUC score in the range of 0.985 to 0.989, accuracy in the range of 0.986 to 0.99 and F-Measure in range of 0.98 to 0.985. The study also identifies smoking habits, exposure to air pollution, occupational hazards and some clinical symptoms as the most commonly selected lung cancer risk prediction features. The study concludes that the developed lung cancer risk prediction models can be successfully applied for early screening, diagnosis and treatment of high-risk individuals.
APA, Harvard, Vancouver, ISO, and other styles
8

Vengoechea, Jose Javier, Manuel Ponce-Alonso, Ana Lucía Figueredo, Elisa Mincholé, Rosa Del Campo, and Salvador Bello. "Lung Micobiome in Lung Cancer." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.1770.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Baum, Philip, and Marten Dooper. "Decline in lung cancer mortality is almost exclusive to men." In European Lung Cancer Congress 2022, edited by Stefan Rauh. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/b3865180.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Käsmann, Lukas, and Marten Dooper. "No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC." In European Lung Cancer Congress 2022, edited by Stefan Rauh. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/3640a321.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Lung cancer"

1

Freire, Mariana, Diana Martins, Maria Filomena Botelho, and Fernando Mendes. Biomarkers of resistance mechanisms in innovative lung cancer treatments - A systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0011.

Full text
Abstract:
Review question / Objective: This systematic review aims to provide an overview of the immunotherapy resistance mechanisms and identify potential biomarkers associated with immunotherapy response in NSCLC, as well as examine new treatment options to overcome this hurdle. Condition being studied: Lung Cancer (LC) remains one of the leading cancers worldwide. In 2020, were globally estimated 2 206 771 new cases and 1 796 144 deaths, representing the uttermost frequent cause of cancer death. LC is classified histologically into small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC), being the last one the most common, representing 80 to 85% of all LC. The three predominantly subtypes of NSCLC are lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and large cell carcinoma (LCLC). NSCLC is usually diagnosed in advanced-staged disease due to ambiguous and delayed severe symptoms.
APA, Harvard, Vancouver, ISO, and other styles
2

Wang, Yan, Wenpeng Song, Sicheng Zhou, Jie Tian, Yingxian Dong, Jue Li, Junke Chang, et al. Increased risk for subsequent primary lung cancer among female hormone-related cancer patients: a meta-analysis based on over four million cases. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0044.

Full text
Abstract:
Review question / Objective: To identify the risk of lung cancer in FHRC patients compared to the general population. Condition being studied: The incidence rate of lung cancer in women is obviously increasing over the past decade and previous evidence have indicated the significant relationship between disturbances in hormone levels and the risk of lung cancer. Therefore, we hypothesized female hormone-related cancer (FHRC), including the breast, endometrial, cervix, and ovary cancer, patients may experience a higher risk of developing subsequent lung cancer.
APA, Harvard, Vancouver, ISO, and other styles
3

Danny Colombara, Danny Colombara. Viral Causes of Lung Cancer. Experiment, December 2012. http://dx.doi.org/10.18258/0065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kang, Jing, Jun Zhang, Zongsheng Tian, Ye Xu, Jiangbi Li, and Mingxina Li. The efficacy and safety of immune-checkpoint inhibitor plus chemotherapy versus chemotherapy for non-small cell lung cancer: an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0156.

Full text
Abstract:
Review question / Objective: Population: histologically confirmed advanced NSCLC patients; Intervention: received immune-checkpoint inhibitor plus chemotherapy; Comparison:received chemotherapy; Outcome: reported OS, PFS, ORR and TRAEs; Study design: RCT. Condition being studied: Lung cancer is the primary cause of cancer-related deaths, with an estimated 2.20 million new cases and 1.79 million deaths every year, and 85% of all primary lung cancers are non-small cell lung cancer. Eligibility criteria: Studies were considered eligible if they met the following criteria: (1) being an randomized controlled trial published in English, (2) histologically confirmed advanced NSCLC patients, (3) reported OS, PFS, ORR and TRAEs, (4) the intervention group received immune-checkpoint inhibitor plus chemotherapy, while the control group received chemotherapy, (5) When numerous papers reporting the same trial were found, the most current or most complete publications were chosen. The following were the exclusion criteria: (1) duplicate articles, (2) reviews, meta-analyses, case reports, editorials and letters, (3) molecular biology or animal research, (4) retrospective or prospective observational cohort studies.
APA, Harvard, Vancouver, ISO, and other styles
5

Gilbert, Jennifer, Stephanie Veazie, Kevin Joines, Kara Winchell, Rose Relevo, Robin Paynter, and Jeanne-Marie Guise. Patient Navigation Models for Lung Cancer. Agency for Healthcare Research and Quality (AHRQ), December 2018. http://dx.doi.org/10.23970/ahrqepcrapidlung.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Panyam, Jayanth. Targeted Magnetic Hyperthermia for Lung Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2012. http://dx.doi.org/10.21236/ada568987.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Panyam, Jayanth. Targeted Magnetic Hyperthermia for Lung Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2013. http://dx.doi.org/10.21236/ada592043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Grando, Sergei. Nicotinic Receptor Polymorphism in Lung Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2013. http://dx.doi.org/10.21236/ada598342.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Panyam, Jayanth. Targeted Magnetic Hyperthermia for Lung Cancer. Fort Belvoir, VA: Defense Technical Information Center, November 2014. http://dx.doi.org/10.21236/ada620276.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Liu, JIe, Xu-li Yang, Xing Liu, Yan Xu, and He-lang Huang. Predictors of readmission after pulmonary resection in patients with lung cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0049.

Full text
Abstract:
Review question / Objective: At present, risk factors for readmission after pulmonary resection in patients with lung cancer are still not fully elucidated, and related studies have shown inconclusive results. We conducted a meta-analysis of the existing literature with the aim of clarifying the risk factors for readmission and providing evidence for the prevention of readmission after surgical resection in patients with lung cancer. Eligibility criteria: Included articles needed to meet the following criteria: (I) the full article could be retrieved and had sufficient data for extraction; (II) the study focused on risk factors for readmission after pulmonary resection for lung cancer; and (III) patients were readmitted to the same institution. Studies were excluded if: (I) they were abstracts, letters, reviews, or case reports; (II) patients were readmitted to the emergency department or there was early return to the clinic; and (III) study contained repeated data or did not report the outcomes of interest.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Lung cancer' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography